A Phase 2 interventional study of AT-1501 in IgA Nephropathy and IgAN, sponsored by Eledon Pharmaceuticals. Terminated at 26 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Eledon Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Glomerulonephritis, IGA with a site in Malaysia — 6 open to participants now, 10 under way, 8 of them phase 3. Glomerulonephritis, IGA · Malaysia.
Among the 20 studies in Glomerulonephritis, IGA with a site in Malaysia, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2022, is one of 8 in phase 2, and was the 9th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →6 of the 20 studies in Glomerulonephritis, IGA with a site in Malaysia are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Malaysia, United States, Argentina and 6 more countries
Ages 18–100
Biogen · Sites in Malaysia, United States, Argentina and 25 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Malaysia, United States, Argentina and 2 more countries
Ages 18–99
Walden Biosciences · Sites in Malaysia, United States, Australia and 4 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in Malaysia, United States, Argentina and 33 more countries
Ages 18–100
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 10
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 220 across the 19 interventional studies, 211 across the 1 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 20 have an industry lead sponsor. The 10 most frequent:
Eledon Pharmaceuticals is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Eledon Pharmaceuticals has 1 study filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
4 of the studies in Glomerulonephritis, IGA with a site in Malaysia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT06797518Novartis PharmaceuticalsStudy to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | 2027-11-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Glomerulonephritis, IGA with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
Phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of Screening. Up to 42 eligible patients will receive one of 2 doses of AT-1501. All patients are scheduled to receive AT-1501 by intravenous infusion every 3 weeks for approximately 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.
Drug: AT-1501
AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions
Drug: AT-1501
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Efficacy - change in participants UPCR
The change in 24-hour urine protein to creatinine ratio (UPCR) from baseline to 24 weeks
Time frame: Up to 24 weeks
Safety- Number of participants with treatment related adverse events
Incidence of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs of special interest (AEoSI)
Time frame: Through study completion, an average of 100 weeks
Change in eGFR slope
The change in eGFR slope from baseline to 96 weeks
Time frame: Baseline- 96 weeks
Change in urine protein excretion (mg/mg)
The change in urine protein excretion over time
Time frame: Up to 96 weeks
Development of Anti drug Antibodies (ADAs)
The percentage of participants who develop ADAs
Time frame: Up to 96 weeks
Exploratory- Change in baseline serum biomarkers
The change in serum biomarkers from baseline to completion of study
Time frame: Through study completion, an average of 100 weeks
Ran from Mar 2022 to primary completion in Jul 2023, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprubart
Eledon Pharmaceuticals